133 related articles for article (PubMed ID: 38309277)
1. Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor.
Su LY; Tian Y; Zheng Q; Cao Y; Yao M; Wang S; Xu W; Xi C; Clocchiatti A; Nie G; Zhou H
Cell Chem Biol; 2024 Jun; 31(6):1219-1230.e5. PubMed ID: 38309277
[TBL] [Abstract][Full Text] [Related]
2. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras.
Ahn G; Riley NM; Kamber RA; Wisnovsky S; Moncayo von Hase S; Bassik MC; Banik SM; Bertozzi CR
Science; 2023 Oct; 382(6668):eadf6249. PubMed ID: 37856615
[TBL] [Abstract][Full Text] [Related]
3. Lysosome-Targeting Bacterial Outer Membrane Vesicles for Tumor Specific Degradation of PD-L1.
Ji P; Wu P; Wang L; Wang Y; Guo X; Gao R; Guo Z; Zhou H; Liu Z; Liang Y; Lu F; Yang G; Ji G
Small; 2024 Jun; ():e2400770. PubMed ID: 38934533
[TBL] [Abstract][Full Text] [Related]
4. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.
Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S
J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581
[TBL] [Abstract][Full Text] [Related]
5. Engineered Bacterial Outer Membrane Vesicles with Lipidated Heterologous Antigen as an Adjuvant-Free Vaccine Platform for Streptococcus suis.
Li Q; Zhou G; Fei X; Tian Y; Wang S; Shi H
Appl Environ Microbiol; 2023 Mar; 89(3):e0204722. PubMed ID: 36809058
[TBL] [Abstract][Full Text] [Related]
6. Covalent LYTAC Enabled by DNA Aptamers for Immune Checkpoint Degradation Therapy.
Li Y; Liu X; Yu L; Huang X; Wang X; Han D; Yang Y; Liu Z
J Am Chem Soc; 2023 Nov; ():. PubMed ID: 37910771
[TBL] [Abstract][Full Text] [Related]
7. Lysosome-targeting chimaeras for degradation of extracellular proteins.
Banik SM; Pedram K; Wisnovsky S; Ahn G; Riley NM; Bertozzi CR
Nature; 2020 Aug; 584(7820):291-297. PubMed ID: 32728216
[TBL] [Abstract][Full Text] [Related]
8. Semiconducting Polymer Nanoparticles with Surface-Mimicking Protein Secondary Structure as Lysosome-Targeting Chimaeras for Self-Synergistic Cancer Immunotherapy.
Qi J; Jia S; Kang X; Wu X; Hong Y; Shan K; Kong X; Wang Z; Ding D
Adv Mater; 2022 Aug; 34(31):e2203309. PubMed ID: 35704513
[TBL] [Abstract][Full Text] [Related]
9. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
[TBL] [Abstract][Full Text] [Related]
10. Conjugation with glucagon like peptide-1 enables targeted protein degradation.
Zhu L; Zhou Y; Zhang B; Luo Y; Fang C; Yan X; Cai Y; Jiang L; Ge J
Bioorg Chem; 2023 Dec; 141():106908. PubMed ID: 37827016
[TBL] [Abstract][Full Text] [Related]
11.
Liang R; Li P; Yang N; Xiao X; Gong J; Zhang X; Bai Y; Chen Y; Xie Z; Liao Q
Drug Des Devel Ther; 2024; 18():1833-1853. PubMed ID: 38828018
[TBL] [Abstract][Full Text] [Related]
12. Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system.
Jin M; Huo D; Sun J; Hu J; Liu S; Zhan M; Zhang BZ; Huang JD
J Nanobiotechnology; 2024 Jan; 22(1):15. PubMed ID: 38166929
[TBL] [Abstract][Full Text] [Related]
13. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
14. Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy
Li Y; Zhao R; Cheng K; Zhang K; Wang Y; Zhang Y; Li Y; Liu G; Xu J; Xu J; Anderson GJ; Shi J; Ren L; Zhao X; Nie G
ACS Nano; 2020 Dec; 14(12):16698-16711. PubMed ID: 33232124
[TBL] [Abstract][Full Text] [Related]
15. Engineered Bacterial Outer Membrane Vesicles as Controllable Two-Way Adaptors to Activate Macrophage Phagocytosis for Improved Tumor Immunotherapy.
Feng Q; Ma X; Cheng K; Liu G; Li Y; Yue Y; Liang J; Zhang L; Zhang T; Wang X; Gao X; Nie G; Zhao X
Adv Mater; 2022 Oct; 34(40):e2206200. PubMed ID: 35985666
[TBL] [Abstract][Full Text] [Related]
16. Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy.
Park KS; Svennerholm K; Crescitelli R; Lässer C; Gribonika I; Lötvall J
J Extracell Vesicles; 2021 Jul; 10(9):e12120. PubMed ID: 34262675
[TBL] [Abstract][Full Text] [Related]
17. ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation.
Sun R; Meng Z; Lee H; Offringa R; Niehrs C
Cell Chem Biol; 2023 Jul; 30(7):739-752.e8. PubMed ID: 37321224
[TBL] [Abstract][Full Text] [Related]
18. IGF2 Peptide-Based LYTACs for Targeted Degradation of Extracellular and Transmembrane Proteins.
Mikitiuk M; Barczyński J; Bielski P; Arciniega M; Tyrcha U; Hec A; Lipińska AD; Rychłowski M; Holak TA; Sitar T
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005242
[TBL] [Abstract][Full Text] [Related]
19. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1.
Zhang N; Dou Y; Liu L; Zhang X; Liu X; Zeng Q; Liu Y; Yin M; Liu X; Deng H; Song D
EBioMedicine; 2019 Feb; 40():151-162. PubMed ID: 30711516
[TBL] [Abstract][Full Text] [Related]
20. A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy.
Zhai Y; Ma Y; Pang B; Zhang J; Li Y; Rui Y; Xu T; Zhao Y; Qian Z; Gu Y; Li S
J Nanobiotechnology; 2021 Dec; 19(1):434. PubMed ID: 34930285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
